California biotech
International Stem Cell is developing novel stem cell-based therapies and
biomedical products geared toward unmet medical needs with limited treatment
options. Many such areas already involve clinically proven cell therapy but
lack safe human cells. ISCO’s solution to filling these gaps is the company’s
patented new class of human stem cells called parthenogenetic stem cells.
ISCO’s core technology,
parthenogenesis, enables the creation of pluripotent human stem cells from
unfertilized human eggs. These human parthenogenetic stem cells (hpSCs) avoid
ethical issue associated with the use or destruction of viable human embryos.
As the world’s first
parthenogenetic homozygous stem cell line, ISCO’s hpSCs, which in late 2014
were cleared by the FDA for clinical use, can be immune-matched to millions of
people of differing gender, age and racial background.
Using its patented parthenogenesis
process, ISCO earlier this month completed the manufacturing of the cell bank
of more than 2.6 billion clinical-grade human neural stem cells needed for its
upcoming phase 1/2a clinical trial for the treatment of Parkinson’s disease.
In preparation of the
clinical study, ISCO formed an Australian subsidiary, Cyto Therapeutics Pty
Ltd., designated to manage the regulatory submission to the Australian
Therapeutics Goods Administration (TGA) and the up-and-coming clinical study.
Also included in ISCO’s
subsidiary portfolio is Lifeline Cell Technology, which manufactures and
markets high-quality primary human cells, optimized media and reagents; and
Lifeline Skin Care, developer of branded anti-aging skin care products based on
growth factors and peptides extracted from hpSCs.
In addition to Parkinson’s
disease, ISCO’s scientists are focused on using hpSCs to treat severe diseases
of the eye, the nervous system and the liver.
With 220 patents,
applications and licenses, a broad pipeline of targets, sturdy balance sheet,
and an industry-anticipated clinical trial to launch in mid-2015, ISCO is
well-positioned as a reputable innovator in the advance of stem cell-based
therapies.
For more information,
visit www.internationalstemcell.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment